- MediciNova has an important proof-of-concept catalyst on the horizon for its lead compound, MN-166, or Ibudilast as a treatment for opioid dependency.
- Ibudilast has already been shown to have effect in the treatment of methamphetamine addiction exacting $23B annually from the U.S. economy relative to crime, lost work productivity and healthcare.
- Already having received "fast-track" status in this indication, MediciNova is now in consultation with the FDA to advance this molecule as quickly as possible into commercialization.
- MediciNova also recently received a milestone payment equaling eight months of operating capital for its contribution to Genzyme's gene therapy treatment in Parkinson's disease which should relieve downward pressure on the stock.
Biotechnology companies are by and large birthed through...
Only subscribers can access this article, which is part of the PRO research library covering 3,741 different stocks.
Growing numbers of fund managers and other investment professionals subscribe to Seeking Alpha PRO for equity research that is unavailable elsewhere, so they can: